Sunday, November 8, 2026

Litecoin On Bearish Momentum: 3.71% Down In The Last 6 Hours

ViaNews Editorial Team

December 16, 2020

Litecoin On Bearish Momentum: 3.71% Down In The Last 6 Hours

Litecoin is currently on bearish momentum. At 21:03 EST on Tue 15 Dec, Litecoin is at $79.59 and down by 3.71% in the last 6 hours.

Litecoin Range

Over the last six hours, Litecoin's higher value was $82.54 and the lower value was $79.59.

Over the last twelve hours, Litecoin's higher value was $82.54 and the lower value was $79.59.

In relation to Litecoin's daily highs, it's 5.306% down from its trailing 24-hour high of $84.05

In relation to the Litecoin's yearly highs and lows, it's 211.263% up from its 52-week low and 14.95% down from its 52-week high.

News about Bitcoin

What is Bitcoin worth? little consensus in fragmented market. According to The Wall Street Journal on Sun Dec 13, "Bitcoin enthusiasts agree the digital currency hit a record recently. ", "Bitcoin and hundreds of other cryptocurrencies trade on independent exchanges around the world. "

JPMorgan says massmutual’s Bitcoin foray signals widening demand. According to Bloomberg Quint on Mon Dec 14, "If pension funds and insurance companies in the U.S., euro area, U.K. and Japan allocate 1% of assets to Bitcoin, that would result in additional Bitcoin demand of $600 billion, the strategists said. ", "At the same time, traditional investors like insurers and pension portfolios face regulatory hurdles relating to risk levels and liability mismatches, likely limiting how much they can put into Bitcoin, the JPMorgan strategists wrote."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com